FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023000498> ?p ?o ?g. }

• W2023000498 endingPage "3867" @default.
• W2023000498 startingPage "3858" @default.
• W2023000498 abstract "BACKGROUND: The objective of this study was to examine the cost effectiveness of using a pharmacogenetic test for uridine diphosphate glycosyltransferase 1A1*28 (UGT1A1*28) variant homozygosity before administering irinotecan to patients with metastatic colorectal cancer. METHODS: A decision-analytic model from the Medicare payer perspective followed hypothetical patients who were treated with combined 5-fluorouracil, leucovorin, and irinotecan. Under usual care, patients received a full dose of irinotecan. With genetic testing, irinotecan dosage was reduced 25% in homozygotes with the UGT1A1*28 variant allele. Test performance, chemotherapy toxicity, and quality-of-life weights were derived from clinical literature and product labels, and costs were derived from 2007 Medicare fee schedules. Chemotherapy efficacy after dose reduction, adverse event risk, and other parameters were varied in 1-way and probabilistic sensitivity analyses. The authors also calculated the value of investing in further studies of chemotherapy efficacy after homozygote dose reductions. RESULTS: Pretreatment genetic testing costs less ($272 savings per patient tested) and yields slightly improved quality-adjusted life expectancy (0.1 quality-adjusted day per patient tested; approximately 2 quality-adjusted hours). Results depended on treatment efficacy but not adverse event risk assumptions. The results indicated that testing would avoid 84 cases of severe neutropenia, including 4.4 deaths. At a threshold of $100,000 per quality-adjusted life year, the therapeutic efficacy of irinotecan in homozygotes after dose reduction had to be ≥98.4% of full-dose efficacy for genetic testing to remain preferred. Future studies to determine whether this efficacy level can be achieved have an economic value of $22 million. CONCLUSIONS: The current results indicated that pharmacogenetic testing for UGT1A1*28 variant homozygosity may be cost effective, but only if irinotecan dose reduction in homozygotes does not reduce efficacy. Future studies to evaluate reduced-dose efficacy in homozygotes should be considered. Cancer 2009. © 2009 American Cancer Society." @default.
• W2023000498 created "2016-06-24" @default.
• W2023000498 creator A5009072858 @default.
• W2023000498 creator A5081836510 @default.
• W2023000498 creator A5086581232 @default.
• W2023000498 creator A5087821944 @default.
• W2023000498 date "2009-09-01" @default.
• W2023000498 modified "2023-09-27" @default.
• W2023000498 title "Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer" @default.
• W2023000498 cites W103706502 @default.
• W2023000498 cites W1979560937 @default.
• W2023000498 cites W1992292837 @default.
• W2023000498 cites W2006824814 @default.
• W2023000498 cites W2011000634 @default.
• W2023000498 cites W2013754529 @default.
• W2023000498 cites W2031436799 @default.
• W2023000498 cites W2038750466 @default.
• W2023000498 cites W2076366897 @default.
• W2023000498 cites W2081258042 @default.
• W2023000498 cites W2095822339 @default.
• W2023000498 cites W2096122707 @default.
• W2023000498 cites W2100082529 @default.
• W2023000498 cites W2104709039 @default.
• W2023000498 cites W2109578477 @default.
• W2023000498 cites W2112727687 @default.
• W2023000498 cites W2119347977 @default.
• W2023000498 cites W2121175754 @default.
• W2023000498 cites W2121503597 @default.
• W2023000498 cites W2123312481 @default.
• W2023000498 cites W2125942822 @default.
• W2023000498 cites W2127532818 @default.
• W2023000498 cites W2127745545 @default.
• W2023000498 cites W2133399075 @default.
• W2023000498 cites W2138404206 @default.
• W2023000498 cites W2144233828 @default.
• W2023000498 cites W2149198543 @default.
• W2023000498 cites W2166209362 @default.
• W2023000498 cites W2170431369 @default.
• W2023000498 cites W2247678173 @default.
• W2023000498 cites W2329791077 @default.
• W2023000498 cites W4250492534 @default.
• W2023000498 doi "https://doi.org/10.1002/cncr.24428" @default.
• W2023000498 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2853177" @default.
• W2023000498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19517472" @default.
• W2023000498 hasPublicationYear "2009" @default.
• W2023000498 type Work @default.
• W2023000498 sameAs 2023000498 @default.
• W2023000498 citedByCount "76" @default.
• W2023000498 countsByYear W20230004982012 @default.
• W2023000498 countsByYear W20230004982013 @default.
• W2023000498 countsByYear W20230004982014 @default.
• W2023000498 countsByYear W20230004982015 @default.
• W2023000498 countsByYear W20230004982016 @default.
• W2023000498 countsByYear W20230004982017 @default.
• W2023000498 countsByYear W20230004982018 @default.
• W2023000498 countsByYear W20230004982019 @default.
• W2023000498 countsByYear W20230004982020 @default.
• W2023000498 countsByYear W20230004982021 @default.
• W2023000498 countsByYear W20230004982022 @default.
• W2023000498 crossrefType "journal-article" @default.
• W2023000498 hasAuthorship W2023000498A5009072858 @default.
• W2023000498 hasAuthorship W2023000498A5081836510 @default.
• W2023000498 hasAuthorship W2023000498A5086581232 @default.
• W2023000498 hasAuthorship W2023000498A5087821944 @default.
• W2023000498 hasBestOaLocation W20230004981 @default.
• W2023000498 hasConcept C104317684 @default.
• W2023000498 hasConcept C121608353 @default.
• W2023000498 hasConcept C126322002 @default.
• W2023000498 hasConcept C135763542 @default.
• W2023000498 hasConcept C143998085 @default.
• W2023000498 hasConcept C185592680 @default.
• W2023000498 hasConcept C197934379 @default.
• W2023000498 hasConcept C2776694085 @default.
• W2023000498 hasConcept C2780259306 @default.
• W2023000498 hasConcept C2780673598 @default.
• W2023000498 hasConcept C526805850 @default.
• W2023000498 hasConcept C55493867 @default.
• W2023000498 hasConcept C55775858 @default.
• W2023000498 hasConcept C71924100 @default.
• W2023000498 hasConceptScore W2023000498C104317684 @default.
• W2023000498 hasConceptScore W2023000498C121608353 @default.
• W2023000498 hasConceptScore W2023000498C126322002 @default.
• W2023000498 hasConceptScore W2023000498C135763542 @default.
• W2023000498 hasConceptScore W2023000498C143998085 @default.
• W2023000498 hasConceptScore W2023000498C185592680 @default.
• W2023000498 hasConceptScore W2023000498C197934379 @default.
• W2023000498 hasConceptScore W2023000498C2776694085 @default.
• W2023000498 hasConceptScore W2023000498C2780259306 @default.
• W2023000498 hasConceptScore W2023000498C2780673598 @default.
• W2023000498 hasConceptScore W2023000498C526805850 @default.
• W2023000498 hasConceptScore W2023000498C55493867 @default.
• W2023000498 hasConceptScore W2023000498C55775858 @default.
• W2023000498 hasConceptScore W2023000498C71924100 @default.
• W2023000498 hasIssue "17" @default.
• W2023000498 hasLocation W20230004981 @default.
• W2023000498 hasLocation W20230004982 @default.
• W2023000498 hasLocation W20230004983 @default.
• W2023000498 hasLocation W20230004984 @default.

• next